POSTMENOPAUSAL OSTEOPOROSIS MARKET ANALYSIS

Postmenopausal Osteoporosis Market, by Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), RANK Ligand Inhibitors, Anabolic Class, Calcium Metabolism Modifiers, and Others (Calcitonin, Denosumab among Others)), by Route of Administration (Oral, Intravenous Route, and Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023
Code : CMI5479
Pages :339
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Companies covered:

Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc. Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed